United States

Profile: Ocular Therapeutix Inc (OCUL.A)

OCUL.A on American Stock Exchange

17 May 2019
Change (% chg)

$-0.06 (-1.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Its first product, ReSure Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

DEXTENZA incorporates the Food and Drug Administration (FDA)-approved corticosteroid dexamethasone as an active pharmaceutical ingredient into a hydrogel-based drug-eluting insert for intracanalicular use. OTX-TP incorporates travoprost, which is an FDA-approved prostaglandin analogue in eye drop form that reduces elevated intraocular pressure (IOP) as its active pharmaceutical ingredient, into a hydrogel-based drug-eluting intracanalicular insert. OTX-TP is being developed as a treatment for glaucoma and ocular hypertension. It is engaged in the preclinical development of its hydrogel depot administered through intravitreal injection. Its product, ReSure Sealant, is a topical liquid hydrogel that creates a temporary, adherent, soft and lubricious sealant to prevent post-surgical leakage from clear corneal incisions that are made during cataract surgery.

The Company competes with Icon Biosciences, Inc., Inotek Pharmaceuticals, Allergan, Inc., ForSight VISION5, Mati Therapeutics, Invisia Therapeutics and Beaver Visitec.

Company Address

Ocular Therapeutix Inc

15 Crosby Dr
BEDFORD   MA   01730-1401
P: +1781.8953235
F: +1781.3574001

Company Web Links